---
title: "Berkshire, Novo and Hims | Henri Blomster, Jesse Viljanen | Negotiator 330"
titleOriginal: "Berkshire Novo Hims | Henri Blomster Jesse Viljanen | Neuvottelija 330"
episodeNumber: "330"
guest: "Henri Blomster, Jesse Viljanen"
datePublished: 2025-05-12
duration: "01:00:57"
youtube: "https://www.youtube.com/watch?v=F2z5W48O0Xs"
originalLanguage: "fi"
topics: ["investing_markets"]
subtitleMethod: "none"
provenance: "Owner page assembled from YouTube metadata, the neuvottelija.fi episode record and the publisher's own chapter marks, translated one for one; their spacing is irregular and matches the recording. No transcript is published here — the channel has no English caption track for this episode and the Finnish one is YouTube's automatic track. All three participants hold positions in the companies discussed and say so in the episode; nothing in it is investment advice, and the long-form write-up in the Neuvottelija AI editions repeats both points."
fiCanonical: "https://www.neuvottelija.fi/fi/episodes/611-berkshire-novo-hims-blomster-viljanen-neuvottelija-330"
canonical: https://www.neuvottelija.com/podcast/episodes/ep330-berkshire-novo-hims-henri-blomster-jesse-viljanen/
---
# Berkshire, Novo and Hims | Henri Blomster, Jesse Viljanen | Negotiator 330

English subtitles are not available on this page. This is an episode summary, not a curated transcript.

## Chapters

- [00:00](https://www.youtube.com/watch?v=F2z5W48O0Xs&t=0s) Warren Buffett, Jesse Viljanen and Henri Blomster of Asilo Asset Management
- [00:52](https://www.youtube.com/watch?v=F2z5W48O0Xs&t=52s) Hims & Hers up 700 per cent, and the pharmaceutical angle
- [01:42](https://www.youtube.com/watch?v=F2z5W48O0Xs&t=102s) Buffett fandom, gym equipment, Berkshire mugs and merch ideas
- [02:30](https://www.youtube.com/watch?v=F2z5W48O0Xs&t=150s) An Inner Circle idea, and memories of the Berkshire meeting
- [02:58](https://www.youtube.com/watch?v=F2z5W48O0Xs&t=178s) Heikki Keskiväli as sherpa: the meeting beat expectations
- [03:52](https://www.youtube.com/watch?v=F2z5W48O0Xs&t=232s) Queuing for front-row seats, and Buffett's criticism of property
- [04:37](https://www.youtube.com/watch?v=F2z5W48O0Xs&t=277s) Investment flats, and the difference between Munger's and Buffett's styles
- [05:48](https://www.youtube.com/watch?v=F2z5W48O0Xs&t=348s) A fans' festival, soft Q1 results, and the best holding period being forever
- [07:30](https://www.youtube.com/watch?v=F2z5W48O0Xs&t=450s) Greg Abel, the energy unit's results, and the anointed successor
- [09:41](https://www.youtube.com/watch?v=F2z5W48O0Xs&t=581s) Coca-Cola, the difficulty of Buffett's scale, and the need to change strategy
- [11:20](https://www.youtube.com/watch?v=F2z5W48O0Xs&t=680s) AmEx, the growth of card companies, and ecosystem thinking
- [13:05](https://www.youtube.com/watch?v=F2z5W48O0Xs&t=785s) The Japanese investments, and the shortage of things to buy
- [14:57](https://www.youtube.com/watch?v=F2z5W48O0Xs&t=897s) The motivational value of cash flow to an investor
- [16:57](https://www.youtube.com/watch?v=F2z5W48O0Xs&t=1017s) Dividends in an investment strategy, and their tax effects
- [18:53](https://www.youtube.com/watch?v=F2z5W48O0Xs&t=1133s) Berkshire's buybacks, and book value as the threshold
- [20:21](https://www.youtube.com/watch?v=F2z5W48O0Xs&t=1221s) Allocating to a global index: euro against the US
- [22:08](https://www.youtube.com/watch?v=F2z5W48O0Xs&t=1328s) The UK–US tariff deal, and the mood in European business
- [24:23](https://www.youtube.com/watch?v=F2z5W48O0Xs&t=1463s) Renewed faith in European companies, and scepticism about it
- [26:20](https://www.youtube.com/watch?v=F2z5W48O0Xs&t=1580s) Novo Nordisk's results, and its position against Eli Lilly
- [28:08](https://www.youtube.com/watch?v=F2z5W48O0Xs&t=1688s) Differences in efficacy between obesity drugs, and production questions
- [29:58](https://www.youtube.com/watch?v=F2z5W48O0Xs&t=1798s) A critique of momentum investing, and Novo outsourcing production
- [31:40](https://www.youtube.com/watch?v=F2z5W48O0Xs&t=1900s) The royalty question, and compounder risk falling from H2 on
- [33:40](https://www.youtube.com/watch?v=F2z5W48O0Xs&t=2020s) New formulations: long-acting and oral
- [35:19](https://www.youtube.com/watch?v=F2z5W48O0Xs&t=2119s) Experimental science, mental models and investment psychology
- [37:43](https://www.youtube.com/watch?v=F2z5W48O0Xs&t=2263s) Hims & Hers solving everyday problems, and the telehealth pigeonhole
- [40:09](https://www.youtube.com/watch?v=F2z5W48O0Xs&t=2409s) Real options, and Hims outside the insurance-physician complex
- [42:42](https://www.youtube.com/watch?v=F2z5W48O0Xs&t=2562s) Volatility, B2C risk, and the insurers' point of view
- [44:55](https://www.youtube.com/watch?v=F2z5W48O0Xs&t=2695s) Share price swings, Hims's competitive advantages and where it saves
- [50:38](https://www.youtube.com/watch?v=F2z5W48O0Xs&t=3038s) The Amazon and AWS comparison, and AI's role in Hims's growth
- [54:59](https://www.youtube.com/watch?v=F2z5W48O0Xs&t=3299s) Building verticals, and a scalable playbook
- [56:55](https://www.youtube.com/watch?v=F2z5W48O0Xs&t=3415s) Oura and wellbeing data: personal experience
- [58:19](https://www.youtube.com/watch?v=F2z5W48O0Xs&t=3499s) A Samsung competitor, the Apple Watch, and interest in devices
- [1:00:32](https://www.youtube.com/watch?v=F2z5W48O0Xs&t=3632s) Henri's hundred-bagger idea: flying cars and a possible sector winner

## Summary

Three investors work through three companies: the aftermath of Berkshire Hathaway's Omaha meeting, Novo Nordisk's position against Eli Lilly, and Hims & Hers. No investment advice is given and that is said out loud several times; all three hold positions in the companies discussed. On Berkshire the episode covers the 347 billion dollar cash pile Buffett says he does not want, GEICO's turnaround under Todd Combs, the Japanese trading houses, and why the ten per cent ownership ceiling constrains further buying. On Novo, Jesse Viljanen argues the share is far off its highs although the gap to Eli Lilly is small — and that efficacy is not the only criterion, because safety and manufacturing capacity decide. Henri Blomster argues Hims & Hers is mispriced because the market files it as a telehealth company.

## Three companies, one caveat

The caveat comes first because the episode puts it first: everyone at the table owns the
shares they are discussing, and no investment advice is given. What remains is the
reasoning, which is worth more than the conclusions.

## The arguments worth keeping

On Novo, the point that generalises is that efficacy is not the deciding criterion in
obesity drugs — safety and manufacturing capacity are, and a valuation gap built on
efficacy alone is measuring the wrong thing. On Hims the argument is about
classification: the claim is that the market has filed it as a telehealth company and
priced it accordingly. On Berkshire the binding constraint is size, not judgement — the
ten per cent ownership ceiling and the sheer scale of the cash decide what can be bought.


## Watch

The recording lives on the Neuvottelija channel: [Berkshire Novo Hims | Henri Blomster Jesse Viljanen | Neuvottelija 330](https://www.youtube.com/watch?v=F2z5W48O0Xs).
A Finnish edition of this episode is published at [www.neuvottelija.fi](https://www.neuvottelija.fi/fi/episodes/611-berkshire-novo-hims-blomster-viljanen-neuvottelija-330).

## In depth

The Neuvottelija AI editions carry a long-form write-up of this episode:
[English](https://www.neuvottelija.com/ai/ep330-berkshire-novo-hims-henri-blomster-jesse-viljanen/) · [suomeksi](https://www.neuvottelija.fi/economy/ep330-berkshire-novo-hims-henri-blomster-jesse-viljanen/).

---

Cite as: Sami Miettinen, Neuvottelija — Berkshire, Novo and Hims | Henri Blomster, Jesse Viljanen | Negotiator 330, https://www.neuvottelija.com/podcast/episodes/ep330-berkshire-novo-hims-henri-blomster-jesse-viljanen/, 2025-05-12. For quotes include episode 330 and timestamp.